Autres langues Egetis Therapeutics AB

Actions

EGTX

SE0003815604

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:29:47 06/05/2024			Varia. 5j.	Varia. 1 janv.
6,11 ^SEK	-5,56%		+4,09%	+9,50%

03/05	Egetis Therapeutics AB (publ) publie ses résultats pour le premier trimestre clos le 31 mars 2024	CI
22/02	Egetis Therapeutics AB (publ) publie ses résultats pour le quatrième trimestre clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Bulletin from Egetis Therapeutics’ Annual General Meeting 2024	06/05
Egetis Therapeutics Q1 2024 - EU launch closing in	06/05
Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05
The Nomination Committee adjusts its proposal for the annual general meeting of Egetis Therapeutics AB (publ)	24/04
Egetis Therapeutics' : 2023 Annual Report published	15/04
Egetis Therapeutics’ 2023 Annual Report published	15/04
Egetis Therapeutics : NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)	29/03
Egetis Therapeutics - Continued progress in Q4	23/02
Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Egetis Therapeutics : – Corporate Presentation December 2023	27/12
Egetis recruits Laetitia Szaller as General Counsel and Head of Compliance	22/12
Egetis Therapeutics AB Appoints Laetitia Szaller as General Counsel and Head of Compliance	22/12
Egetis highlights recent major milestones, status of ReTRIACt trial and gives a corporate update at Investor Day in Stockholm today	19/12
Egetis’ Investor Day on December 19: Agenda and Registration Details	14/12
Egetis provides update on disease awareness and the Expanded Access Program for tiratricol (Emcitate) in the USA	13/12
Egetis Therapeutics AB Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol in the USA	13/12
Save the Date: Egetis to host Investor Day on December 19, 2023	01/12
Egetis Therapeutics Grants Fujimoto Pharmaceutical Exclusive Rights to Emcitate in Japan; Stock Rises	10/11
Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan	10/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Egetis Therapeutics AB

Actions

EGTX

SE0003815604

Autres langues

Filtres